MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia

NCT00911066 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: MLN4924
DRUG: Azacitidine

Sponsor

Millennium Pharmaceuticals, Inc.